Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Assessment of an association between the use of Disease-modifying agents and the reporting of malignant or unspecified Cancer in patients with Multiple Sclerosis

Next Previous
Trial Profile

Assessment of an association between the use of Disease-modifying agents and the reporting of malignant or unspecified Cancer in patients with Multiple Sclerosis

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 24 May 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alemtuzumab (Primary) ; Cladribine (Primary) ; Dimethyl fumarate (Primary) ; Fingolimod (Primary) ; Glatiramer acetate (Primary) ; Interferon beta-1b (Primary) ; Natalizumab (Primary) ; Ocrelizumab (Primary) ; Ozanimod (Primary) ; Peginterferon beta-1a (Primary) ; Siponimod (Primary) ; Teriflunomide (Primary) ; Interferon beta-1a
  • Indications Multiple sclerosis
  • Focus Adverse reactions

Most Recent Events

  • 24 May 2021 New trial record
  • 16 May 2021 Results published in the British Journal of Clinical Pharmacology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top